{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:41:50Z","timestamp":1756384910703,"version":"3.40.4"},"reference-count":16,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,5,29]]},"abstract":"<jats:p>Richter's transformation is a rare clinical condition occurring in about 5\u201310% of patients with chronic lymphocytic leukaemia (CLL). Patients usually present with lymphadenopathy, hepatosplenomegaly and elevated serum lactate dehydrogenase levels. These patients have a very poor prognosis with a median survival of about 10\u2005months. We present a patient, with a history of CLL in complete remission, who presented with splenic rupture requiring splenectomy. She was eventually diagnosed with diffuse large B-cell lymphoma with Richter's transformation.<\/jats:p>","DOI":"10.1136\/bcr-2016-214361","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T16:26:40Z","timestamp":1465576000000},"page":"bcr2016214361","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Richter's transformation presenting as splenic rupture after 6 years of complete remission of chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"2016","author":[{"given":"Braghadheeswar","family":"Thyagarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayee Sundar","family":"Alagusundaramoorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lopa","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-6449","authenticated-orcid":false,"given":"Abhinav","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.2","first-page":"621","article-title":"[chronic lym- phoid leukemia secondarily associated with a malignant reticulopathy: Richter's syndrome]","volume":"4","author":"Lortholary","year":"1964","journal-title":"Nouv Rev Fr Hematol"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.3","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903515192"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07166.x"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.5","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.664845"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.6","first-page":"1146","article-title":"Richter's transformation in chronic lymphocytic leukemia","volume":"26","author":"Jain","year":"2012","journal-title":"Oncology (Williston Park, NY)"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-302174"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.09.007"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.9","doi-asserted-by":"publisher","DOI":"10.1002\/hon.880"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.10","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1993.11.10.1985","article-title":"Richter's syndrome: a report on 39 patients","volume":"11","author":"Robertson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.11","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20251"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.13","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31804bdaf8"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymph Myel Leuk"},{"key":"2025042703325771000_2016.jun10_1.bcr2016214361.16","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109064589"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-214361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:33:02Z","timestamp":1745749982000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-214361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":16,"alternative-id":["10.1136\/bcr-2016-214361"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-214361","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,6,10]]}}}